Last reviewed · How we verify
Morphine plus Saline (placebo)
Morphine plus Saline (placebo) is a Opioid analgesic Small molecule drug developed by University of California, San Francisco. It is currently in Phase 3 development for Moderate to severe pain (specific indication dependent on trial protocol).
Morphine binds to opioid receptors in the central and peripheral nervous system to reduce pain perception, while saline serves as an inert placebo control.
Morphine plus Saline (placebo) has been studied in clinical trials for various conditions, including postoperative pain, postoperative pain management, and osteoarthritis. However, there is no information available on Morphine plus Saline (placebo) in ClinicalTrials.gov, suggesting it has not been the focus of any registered clinical trials.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Morphine plus Saline (placebo) |
|---|---|
| Sponsor | University of California, San Francisco |
| Drug class | Opioid analgesic |
| Target | Mu-opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Morphine is a mu-opioid receptor agonist that modulates pain signaling by binding to opioid receptors in the brain, spinal cord, and peripheral tissues, thereby reducing the transmission and perception of pain signals. Saline (normal sodium chloride solution) is pharmacologically inert and serves as a control arm in this Phase 3 trial to establish the efficacy of morphine above placebo effect.
Approved indications
- Moderate to severe pain (specific indication dependent on trial protocol)
Common side effects
- Constipation
- Nausea
- Drowsiness
- Dizziness
- Respiratory depression
- Pruritus
Key clinical trials
- Phase II Clinical Study of the Efficacy and Safety of HSK55718 in the Treatment of Abdominal Postoperative Pain (PHASE2)
- PRO-RSTAP: Effect of TAP and RS Blocks on Recovery After Inguinal Hernia Surgery (PRO-RSTAP) (NA)
- Elective Total Abdominal Hysterectomy With Preoperative Analgesia Intravenous Paracetamol Versus Placebo (NA)
- Ketorolac Applied by Continuous IV Infusion for Treatment of Moderately Severe Postoperative Pain Following Bunionectomy (PHASE3)
- Evaluation of the Efficacy of the Addition of Magnesium Sulfate to Morphine on the Occurrence of Acute Urinary Retention Following Epidural Anesthesia for Cesarean Section. (PHASE4)
- Continuous Wound Catheter Analgesia Associated With Intravenous Morphine PCA After Thoracotomy (PHASE4)
- Intrathecal Non-preservative-free Morphine With Bupivacaine Versus Intrathecal Bupivacaine Alone for Analgesia in Unilateral Inguinal Hernia Repair Surgeries (PHASE3)
- Efficacy of Sublingual Midazolam in Association With Oral Morphine in Children Analgesia After Bone Fracture (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Morphine plus Saline (placebo) CI brief — competitive landscape report
- Morphine plus Saline (placebo) updates RSS · CI watch RSS
- University of California, San Francisco portfolio CI
Frequently asked questions about Morphine plus Saline (placebo)
What is Morphine plus Saline (placebo)?
How does Morphine plus Saline (placebo) work?
What is Morphine plus Saline (placebo) used for?
Who makes Morphine plus Saline (placebo)?
What drug class is Morphine plus Saline (placebo) in?
What development phase is Morphine plus Saline (placebo) in?
What are the side effects of Morphine plus Saline (placebo)?
What does Morphine plus Saline (placebo) target?
Related
- Drug class: All Opioid analgesic drugs
- Target: All drugs targeting Mu-opioid receptor (OPRM1)
- Manufacturer: University of California, San Francisco — full pipeline
- Therapeutic area: All drugs in Pain Management
- Indication: Drugs for Moderate to severe pain (specific indication dependent on trial protocol)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing